Economic Financial Indicators

A clear company Mission to pursue with a specific strategic planning, the control on its realization, the continuous survey of the adopted business model towards the change of competitive scenario have allow Abiogen to reach important quality results in the three-year term 2014-2016. The total revenues in 2016 continue its double-figure growing (+ 16%) consolidating 2015 data (+13%) even if a different extent inside the single business areas. In 2016 the commercial revenues have confirmed the growth (+14%), which was already clear in 2015, thanks to the consolidation and further boost of the product portfolio, particularly the ones coming from in-house development so with better marginality. Important results have been reached in the Manufacturing area where we are realizing the adopted industrial strategy fruits: the revenues have increased by 42% respect to 2015 and, considering that the Contract Manufacturing activity is influenced by the kind of production (full service or semi finished product) and by the customers commercial dynamics, the obtained result is much more prominent. Abiogen Pharma’s economic and financial growth is well represented by the positive trend of the fundamental indicators: in 2016 the EBITDA has continued its performance stabilizing at 72 million Euros, (EBITDA ratio 45%), with 25% increase respect to 2015. The above mentioned results turn into an important cash flow which, thanks to an increasing efficiency in the circulating capital management, has led to a widely positive financial position. Finally, the equity is constantly increasing thanks to the obtained results and to the reinvestment of part of the profits generated by the Company.

Consolidated Values (in Euro x1000)

Revenues201620152014
Manufacturing 16.333,00 11.477,00 9.803,58
Variation % +42,31% +17,07% -15,68%
Marketing & Sales 140.368,00 123.110,00 108.093,75
Variation % +14,02% +13,89% +16,68%
Royalties & Downpayments 224,00 252,00 630,00
Variation % -11,11% -60,00% -32,62%
Total 156.925,00 134.829,00 118.527,33
Variation % +16,38% +13,76% +12,66%
Results(Thousand of Euro)201620152014
Turnover 156.925,00 134.839,00 118.527,33
Variation % +16,38% +13,76% +12,66%
Industrial margin 123.144,00 105.766,00 90.137,00
Variation % +16,43% +17,34% +9,14%
EBITDA 72.048,00 57.525,00 46.269,00
Variation % +25,25% +24,33% +30,52%
EBIT 67.047,00 52.387,00 40.256,00
Variation % +27,98% +30,13% +32,71%
Net profit (loss) 44.233,00 34.198,00 25.023,00
Variation % +29,34% +36,67% +36,66%
Net assets 92.192,00 75.143,00 61.313,00
Variation % +22,69% +22,56% +20,37%
Net capital invested 59.584,00 57.358,00 57.105,00
Variation % 3,88% 0,44% -5,49%
Net financial debits 32.608,00 18.135,00 -4.209,00
Variation % 79,81% 330,86% -231,74%